Investing in the New Future of Cancer Therapy
TILT Biotherapeutics (Tiltbio) is the world’s leading company developing investigational oncolytic immunotherapies to enable T-cell therapy for solid tumors.
Tiltbio offers an innovative investment opportunity that supports transforming the standard of care for advanced solid cancer tumor treatment.
The company’s strong intellectual property, a proprietary platform called TILT® technology, is based on decades of biotech, oncology practice, and research experience by founding CEO, Akseli Hemminki, M.D., PhD., and a highly regarded team of experienced industry professionals.
Tiltbio’s clinical development roadmap includes multiple promising products in its pipeline and collaboration with industry-leading pharmaceutical companies like Merck & Co. and Merck KGgA
The company’s lead candidate, TILT-123 (igrelimogene Iitadenorepvec) shows systemic effects in advanced solid tumors. Several Phase I studies have been completed with excellent safety profile so far. In a Phase Ia study in 15 ovarian cancer patients, disease control was achieved in 64% of patients. TILT-123 is now in Phase Ib for ovarian cancer.
Our Funding
TILT Biotherapeutics was formed in 2013 and has secured more than 70 M€ of funding (about 75% from equity and the rest in non-dilutive funding) from investors that include:
- European Innovation Council (EIC Fund)
- Lifeline Ventures
- Finnish Industry Investment Ltd (Tesi)
- Stephen Industries Inc Ltd.
- Growth investment firm Springvest Oyj and Finnish private investors
- Business Finland
- U.S. Department of Defence
The latest equity investment round was completed in March 2025. This Series B funding is used mainly for Phase Ib/II development of TILT-123.
For more information on investing in Tiltbio, please contact bd@tiltbio.com.